MdxHealth (TM) : MDxHealth Announces Presentations on the ConfirmMDx(TM) for Prostate Cancer Test at the ASCO Genitourinary

 MdxHealth (TM) : MDxHealth Announces Presentations on the ConfirmMDx(TM) for
    Prostate Cancer Test at the ASCO Genitourinary Cancers Symposium 2013

IRVINE, CA,  and LIEGE,  BELGIUM -  February  13, 2013  - MDxHealth  SA  (NYSE 
Euronext: MDXH),  a leading  molecular diagnostic  company that  develops  and 
commercializes epigenetic  tests to  support the  diagnosis and  treatment  of 
cancer patients, today announced  that the company  will present results  from 
two important studies involving its ConfirmMDx(TM) for Prostate Cancer test at
the ASCO  Genitourinary  Cancers  Symposium  2013,  February  14-16,  Orlando, 
Florida, USA.

Following are details  for each embargoed  session (all times  are in  Eastern 
Standard Time) follow:

Thursday, February 14, 2013

Abstract Title: Epigenetic  Field Effects for  DNA Methylation Markers  Extend 
Over Multiple Histologically Benign Prostate Biopsy Cores
Lead Author:  Sandra M  Gaston  PhD, New  England Baptist  Hospital,  Harvard 
Medical School
Location: Prostate Cancer poster session: Poster 116
Time: 11:45AM

Abstract Title: Multi-gene  Epigenetic MSP  Assay Predicts  Risk for  Prostate 
Cancer in Histopathologically Negative Biopsies
Lead Author: Leander van Neste PhD, MDxHealth SA, Liege, Belgium
Location: Prostate Cancer poster session: Poster 95
Time: 11:45AM

About ConfirmMDx for Prostate Cancer
Over 650,000 American men receive a negative prostate biopsy result each year;
though approximately 25% of these men may still harbor occult prostate cancer.
This  well-documented  risk  of  undetected  cancer,  often  with   clinically 
significant Gleason scores, leads to a high rate of repeat biopsies with  over 
40% of men receiving at least one repeat biopsy, and many receiving a 3^rd and
4^th biopsy. Today's gold standard diagnostic approach is the prostate  biopsy 
procedure, collecting 10-12 needle core biopsy samples, however this  sampling 
represents less than 1% of a man's prostate. ConfirmMDx for Prostate Cancer is
an epigenetic  assay  to  help  urologists distinguish  patients  who  have  a 
true-negative biopsy from those at risk for occult cancer. The test is able to
detect an epigenetic field effect or "halo" associated with the  cancerization 
process at the  DNA level  in cells adjacent  to cancer  foci. This  molecular 
"halo" around  a  cancer  lesion  can  be  present  despite  having  a  normal 
appearance under the microscope. The  test helps urologists rule out  prostate 
cancer-free men from undergoing unnecessary repeat biopsies and helps rule  in 
high-risk patients who may require repeat biopsies and potential treatment.

About MDxHealth
MDxHealth is a molecular diagnostics company that develops and  commercializes 
advanced epigenetic tests for cancer assessment and the personalized treatment
of patients.  The  company's  first commercial  product,  the  ConfirmMDx  for 
Prostate Cancer test, has been shown  to help distinguish patients who have  a 
true-negative biopsy from those who may have occult cancer. MDxHealth helps to
address a large and growing unmet medical need for better cancer diagnosis and
treatment information. The  company has  a proprietary platform  and a  strong 
epigenetic product pipeline focused on  the development of products for  brain 
and lung cancers. The company is  based in Irvine, California with a  European 
headquarters in Liege, Belgium. For  more information visit MDxHealth  website 
at www.mdxhealth.com.

Contacts 
Dr Jan Groen, CEO
MDxHealth
US: +1 949 812 6979
BE: +32 4 364 20 70
info@mdxhealth.com

Mike Sinclair
Halsin Partners
UK: +44 20 7318 2955
Cell: +44 7968 022075
msinclair@halsin.com

Seth Lewis
The Trout Group
US: +1 646 378 2952
---
slewis@troutgroup.com

This press  release contains  forward-looking  statements and  estimates  with 
respect to the anticipated future performance  of MDxHealth and the market  in 
which it operates. Such statements and estimates are based on assumptions  and 
assessments of known and unknown risks, uncertainties and other factors, which
were deemed reasonable  but may  not prove to  be correct.  Actual events  are 
difficult to predict, may  depend upon factors that  are beyond the  company's 
control, and  may turn  out to  be materially  different. MDxHealth  expressly 
disclaims any obligation to update any such forward-looking statements in this
release to reflect any change in  its expectations with regard thereto or  any 
change in events, conditions or circumstances  on which any such statement  is 
based unless  required by  law  or regulation.  This  press release  does  not 
constitute an offer or  invitation for the sale  or purchase of securities  or 
assets of MDxHealth  in any jurisdiction.  No securities of  MDxHealth may  be 
offered or sold within the United  States without registration under the  U.S. 
Securities Act  of  1933, as  amended,  or  in compliance  with  an  exemption 
therefrom, and in accordance with any applicable U.S. securities laws.

NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are trademarks
or registered trademarks of MDxHealth SA. All other trademarks and service
marks are the property of their respective owners.

ASCO ENG

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: MdxHealth (TM) via Thomson Reuters ONE
HUG#1677471
 
Press spacebar to pause and continue. Press esc to stop.